About CytoDyn (OTCMKTS:CYDY)
CytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the clinical development and commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The Company's lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells. The Company's product pipeline also includes Cytolin and CytoFeline. Cytolin is a mouse monoclonal antibody developed to identify a specific type of immune cell called a cytotoxic T cell, or cytotoxic T lymphocyte (CTL). CytoFeline is an anti-lymphocyte function-associated antigen-1 (LFA-1) antibody for the treatment of Feline Immunodeficiency Virus (FIV) infection. PRO 140 blocks HIV from entering a cell by binding to a molecule called C-C chemokine receptor type 5 (CCR5). The Company has finished Phase II clinical trials for PRO 140 with demonstrated antiviral activity in man.
Industry, Sector and Symbol:
- Industry: N/A
- Sub-Industry: N/A
- Sector: Medical
- Symbol: OTCMKTS:CYDY
- Previous Symbol: NASDAQ:CYDY
- CUSIP: N/A
- Web: www.cytodyn.com
- Current Ratio: 0.39%
- Quick Ratio: 0.39%
Sales & Book Value:
- Annual Sales: N/A
- Price / Sales: N/A
- Book Value: ($0.01) per share
- Price / Book: -60.90
- Trailing EPS: ($0.22)
- Net Income: ($25,760,000.00)
- Return on Equity: -10,003.02%
- Return on Assets: -298.36%
- Employees: 146
- Outstanding Shares: 160,380,000
Frequently Asked Questions for CytoDyn (OTCMKTS:CYDY)
What is CytoDyn's stock symbol?
CytoDyn trades on the OTCMKTS under the ticker symbol "CYDY."
How were CytoDyn's earnings last quarter?
CytoDyn Inc. (OTCMKTS:CYDY) released its earnings results on Tuesday, October, 10th. The biotechnology company reported ($0.08) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.05) by $0.03. View CytoDyn's Earnings History.
When will CytoDyn make its next earnings announcement?
Where is CytoDyn's stock going? Where will CytoDyn's stock price be in 2017?
1 brokerages have issued 12-month price targets for CytoDyn's stock. Their forecasts range from $2.00 to $2.00. On average, they expect CytoDyn's share price to reach $2.00 in the next twelve months. View Analyst Ratings for CytoDyn.
Who are some of CytoDyn's key competitors?
Some companies that are related to CytoDyn include Nymox Pharmaceutical Corporation (NYMX), GTx (GTXI), OncoMed Pharmaceuticals (OMED), Intec Pharma (NTEC), Anavex Life Sciences Corp. (AVXL), CareDx (CDNA), Cogentix Medical (CGNT), Verona Pharma PLC American Depositary Share (VRNA), Signal Genetics (MGEN), Majesco Entertainment Company (COOL), Invuity (IVTY), Cellular Biomedicine Group (CBMG), iRadimed Corporation (IRMD), Quorum Health Corporation (QHC), Nivalis Therapeutics (ALPN), Viralytics (VRACY), SeaSpine Holdings Corporation (SPNE) and Cumberland Pharmaceuticals (CPIX).
Who are CytoDyn's key executives?
CytoDyn's management team includes the folowing people:
- Anthony D. Caracciolo, Independent Chairman of the Board (Age 60)
- Nader Z. Pourhassan Ph.D., President, Chief Executive Officer, Director (Age 52)
- Michael D. Mulholland, Chief Financial Officer, Treasurer, Corporate Secretary (Age 63)
- Denis R. Burger Ph.D., Director (Age 70)
- Carl C. Dockery, Director (Age 52)
- Gregory A. Gould CPA, Independent Director (Age 50)
- A. Bruce Montgomery M.D., Independent Director (Age 63)
- Jordan G. Naydenov, Independent Director (Age 54)
How do I buy CytoDyn stock?
Shares of CytoDyn can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CytoDyn's stock price today?
One share of CytoDyn stock can currently be purchased for approximately $0.61.
How big of a company is CytoDyn?
CytoDyn has a market capitalization of $98.74 million. The biotechnology company earns ($25,760,000.00) in net income (profit) each year or ($0.22) on an earnings per share basis. CytoDyn employs 146 workers across the globe.
How can I contact CytoDyn?
CytoDyn's mailing address is 1111 Main St Ste 660, VANCOUVER, WA 98660-2970, United States. The biotechnology company can be reached via phone at +1-360-9808524 or via email at [email protected]
MarketBeat Community Rating for CytoDyn (OTCMKTS CYDY)MarketBeat's community ratings are surveys of what our community members think about CytoDyn and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for CytoDyn (OTCMKTS:CYDY) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 1 Buy Rating, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$2.00|
Consensus Price Target History for CytoDyn (OTCMKTS:CYDY)
Analysts' Ratings History for CytoDyn (OTCMKTS:CYDY)
(Data available from 11/18/2015 forward)
|8/10/2017||HC Wainwright||Set Price Target||Buy||$2.00|
|10/6/2016||Rodman & Renshaw||Initiated Coverage||Buy||$1.60|
Earnings History and Estimates Chart for CytoDyn (OTCMKTS:CYDY)
Earnings History by Quarter for CytoDyn (OTCMKTS CYDY)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|1/12/2018|| || || || || || || || |
Earnings Estimates for CytoDyn (OTCMKTS:CYDY)
Current Year EPS Consensus Estimate: $-0.17 EPS
Dividend History for CytoDyn (OTCMKTS:CYDY)
No dividend announcements for this company have been tracked by MarketBeat.com
Headline Trends for CytoDyn (OTCMKTS:CYDY)
Latest Headlines for CytoDyn (OTCMKTS CYDY)
CytoDyn (OTCMKTS CYDY) Chart for Saturday, November, 18, 2017